At the annual congress of the Muscular Dystrophy Association (MDA), Swiss pharma giant Roche has announced new data for its spinal muscular atrophy (SMA) drug E 16 March 2022
More positive data for the leading PARP blocker, Lynparza (olaparib), are being presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary 15 February 2022
US pharma giant Merck & Co has announced the final results from the Phase III KEYNOTE-394 trial investigating Keytruda (pembrolizumab) plus best supportive care 19 January 2022
Long-suffering investors in bluebird bio had a rare reason for cheer as the company presented positive results for betibeglogene autotemcel (beti-cel) at the Am 13 December 2021
US pharma major Bristol Myers Squibb has announced the first disclosure of results from a prespecified interim analysis of the pivotal TRANSFORM study at the Am 13 December 2021
At the 63rd annual meeting of the American Society of Hematology (ASH), Swiss pharma giant Novartis (NOVN: VX) has announced new positive data for Scemblix (asc 13 December 2021
Sino-American biotech BeiGene has announced positive results from the Phase III RATIONALE 309 trial of tislelizumab, a checkpoint blocker. 10 December 2021
Virtually every drugmaker with a presence in hematology is preparing for their end-of-year attempt to impress physicians and investors with the best of their fr 10 December 2021
Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia, has shown its efficacy in late-stage trials. 25 November 2021
While injectable PCSK9 inhibitors have long promised an effective way to lower LDL cholesterol levels, relatively low uptake has been blamed on high prices and 16 November 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.